# AI Governance Risk Assessment
## AI Readmission Prevention Model

**Project:** Mission AI 2027  
**System Type:** Predictive Machine Learning / Clinical Decision Support Prototype  
**Governance Framework:** NIST AI Risk Management Framework (AI RMF)  
**Assessment Status:** Portfolio Demonstration  
**Deployment Status:** NOT READY FOR CLINICAL DEPLOYMENT

---

## 1. System Purpose

The AI Readmission Prevention Model is a portfolio demonstration designed to explore how machine learning could help identify patients who may have an elevated risk of hospital readmission.

The prototype uses synthetic patient data and a logistic regression model to estimate readmission risk. Its intended purpose is to demonstrate how predictive analytics could support earlier intervention, resource prioritization, and clinical decision support.

The system is not intended to diagnose patients, prescribe treatment, replace clinical judgment, or autonomously make healthcare decisions.

All outputs should be treated as decision-support information requiring appropriate human review.

---

## Governance Objective

The purpose of this governance assessment is to identify, evaluate, and document the major risks associated with the AI Readmission Prevention Model and establish controls that would be necessary before consideration of any real-world deployment.

The assessment follows the principles of the NIST AI Risk Management Framework, including:

- GOVERN — establish accountability and governance processes.
- MAP — identify the system context, stakeholders, benefits, and risks.
- MEASURE — evaluate and monitor identified risks and system performance.
- MANAGE — prioritize risks and implement appropriate controls.

Responsible deployment requires both technical performance and appropriate human oversight, accountability, transparency, monitoring, and risk management throughout the AI lifecycle.

---

## 2. Stakeholders and Accountability

Effective AI governance requires clearly defined roles, responsibilities, and decision authority throughout the AI lifecycle.

For a potential healthcare readmission risk system, the following stakeholders would have distinct responsibilities:

| Stakeholder | Primary Responsibility |
|---|---|
| Clinical Leadership | Establish appropriate clinical use, validate that model outputs support rather than replace clinical judgment, and approve clinical workflows. |
| Physicians / Care Teams | Interpret model outputs alongside patient-specific information and retain final authority over clinical decisions. |
| Data Science / AI Team | Develop, validate, document, monitor, and maintain the model while communicating known limitations. |
| AI Governance / Risk Team | Evaluate AI risks, establish governance controls, monitor compliance, and coordinate periodic risk reviews. |
| Privacy / Compliance Team | Evaluate data handling, privacy, security, regulatory, and organizational compliance requirements. |
| Hospital Leadership | Establish organizational risk tolerance and provide final authorization for deployment or continued operation. |
| Patients | Individuals potentially affected by decisions informed by the system and therefore key stakeholders in evaluating potential harms and benefits. |

### Accountability Principle

The AI system must never be treated as the final decision-maker.

Clinical professionals retain responsibility for patient-care decisions. Model predictions are intended to provide additional information that may assist clinical teams in identifying patients who could benefit from further evaluation or intervention.

Responsibility for the safe operation of the system is shared across technical, clinical, governance, compliance, and organizational leadership functions, with clearly documented decision authority.

### Human Oversight

Any real-world implementation would require meaningful human oversight.

Healthcare professionals must be able to:

- Review the model's risk classification.
- Consider relevant information not represented in the model.
- Question or override model recommendations.
- Understand documented model limitations.
- Escalate suspected errors or unsafe behavior.
- Make the final clinical decision independently of the AI system.

Automation should support professional judgment rather than substitute for it.

### Deployment Authority

Deployment of the system should require formal approval from appropriate clinical, technical, governance, privacy/compliance, and organizational leadership stakeholders.

No individual model developer should have unilateral authority to approve a high-impact AI system for clinical deployment.

---

## 3. AI Risk Register

The following risk register identifies significant risks that would require evaluation and mitigation before the AI Readmission Prevention Model could be considered for real-world use.

| ID | Risk | Potential Impact | Severity | Primary Control |
|---|---|---|---|---|
| R-01 | Bias or unequal performance across patient groups | Certain populations could receive systematically less accurate risk assessments, potentially contributing to unequal care. | High | Evaluate model performance across relevant demographic and clinical subgroups before deployment and continuously thereafter. |
| R-02 | False negative prediction | A patient at elevated readmission risk could be classified as lower risk and may not receive additional evaluation or intervention. | High | Monitor recall and false-negative rates, establish clinically appropriate thresholds, and require human review rather than relying solely on model output. |
| R-03 | False positive prediction | A lower-risk patient could be classified as high risk, potentially causing unnecessary intervention or inefficient allocation of limited resources. | Medium | Monitor precision and false-positive rates and evaluate the operational consequences of the selected decision threshold. |
| R-04 | Data privacy or inappropriate data use | Patient information could be exposed, improperly accessed, or used beyond its authorized purpose. | High | Apply appropriate privacy, security, access-control, data-governance, and regulatory safeguards before using real patient data. |
| R-05 | Automation bias / overreliance | Healthcare professionals could give excessive weight to model predictions instead of exercising independent clinical judgment. | High | Clearly position outputs as decision support, train users on system limitations, enable overrides, and reinforce human decision authority. |
| R-06 | Model or data drift | Changes in patient populations, clinical practices, or source data could degrade model performance after deployment. | High | Continuously monitor performance and data characteristics and establish thresholds for investigation, recalibration, retraining, or suspension. |
| R-07 | Insufficient explainability or transparency | Users may not understand the factors influencing a prediction or the system's limitations, reducing their ability to appropriately evaluate its output. | Medium | Provide documented model purpose, inputs, limitations, performance characteristics, and appropriate explanation mechanisms for intended users. |
| R-08 | Use outside intended scope | The model could be applied to populations, facilities, workflows, or decisions for which it was never validated. | High | Clearly define intended use, prohibited uses, validated populations, and deployment boundaries. Require governance review before expanding scope. |

### Risk Prioritization

High-severity risks require documented mitigation and validation before deployment approval.

Risk acceptance must not be based solely on aggregate model accuracy. Evaluation should consider potential harm, affected stakeholders, subgroup performance, operational context, human oversight, and the consequences of incorrect predictions.

Risks that cannot be reduced to an acceptable level should result in deployment being delayed, restricted, redesigned, or rejected.

---

## 4. Monitoring and Control Plan

AI governance does not end when a model is approved for use. Any real-world implementation would require ongoing monitoring to determine whether the system continues to operate within acceptable performance, safety, fairness, and operational boundaries.

### Prototype Performance Baseline

The current portfolio prototype established the following experimental performance results using synthetic data:

| Metric | Prototype Result |
|---|---:|
| Test Accuracy | 72.0% |
| Baseline Accuracy | 66.5% |
| F1-Optimized Decision Threshold | 0.25 |
| Precision at Selected Threshold | 47.5% |
| Recall at Selected Threshold | 85.1% |
| F1 Score at Selected Threshold | 61.0% |
| 5-Fold Cross-Validation Accuracy | 71.1% ± 1.6% |
| High-Risk Observed Readmission Rate | 60.8% |
| Low-Risk Observed Readmission Rate | 16.2% |
| High-to-Low Risk Ratio | 3.76x |

These results are evidence from a synthetic portfolio experiment and must not be interpreted as evidence of clinical validity.

### Monitoring Requirements

If the system were ever evaluated for real-world deployment, monitoring should include:

- Overall model discrimination and classification performance.
- Recall and false-negative rate, particularly because missed high-risk patients may have meaningful consequences.
- Precision and false-positive rate to identify unnecessary interventions or inefficient resource allocation.
- Performance across relevant patient subgroups to detect potentially unequal outcomes.
- Changes in input data distributions and missing-data patterns.
- Changes in predicted risk distributions.
- Calibration between predicted risk and observed outcomes.
- Changes in model performance over time.
- Frequency and nature of clinician overrides.
- Reported incidents, unexpected behavior, and user concerns.

### Threshold Governance

The prototype currently uses an F1-optimized threshold of **0.25**, which produced **85.1% recall** and **47.5% precision** in the synthetic test data.

This threshold is an experimental modeling choice, not a clinically validated operating threshold.

Any production threshold would require review with appropriate clinical and governance stakeholders. Threshold selection should consider the relative consequences of false negatives and false positives, available intervention capacity, patient impact, and the organization's established risk tolerance.

A decision threshold must not be moved into production solely because it maximizes a statistical metric.

### Control Actions

Monitoring should be connected to predefined actions rather than treated as passive reporting.

Depending on the severity of an identified issue, potential actions could include:

1. Investigate the model or affected data.
2. Increase human review requirements.
3. Restrict the system's permitted use.
4. Reassess the operating threshold.
5. Recalibrate or retrain the model.
6. Conduct additional validation.
7. Temporarily suspend model use.
8. Permanently retire the system if risks cannot be adequately controlled.

### Change Management

Material changes to the model, input data, target population, decision threshold, clinical workflow, or intended use should trigger documented governance review.

Significant changes should not automatically inherit the approval status of a previous model version.

Model versions, validation results, approvals, identified risks, monitoring findings, incidents, and corrective actions should be documented to maintain an auditable governance history.

---

## 5. Deployment Gates and Go/No-Go Decision

A model should not progress from experimentation to operational deployment solely because it demonstrates promising technical performance.

For a high-impact healthcare use case, deployment should require documented evidence that technical, clinical, governance, privacy, security, and operational requirements have been satisfied.

### Required Deployment Gates

| Gate | Requirement | Current Status |
|---|---|---|
| G-01 | Validation using appropriate real-world representative data | NOT MET |
| G-02 | Independent clinical validation | NOT MET |
| G-03 | Subgroup performance and fairness evaluation | NOT MET |
| G-04 | Privacy and data-governance review | NOT MET |
| G-05 | Security assessment | NOT MET |
| G-06 | Human-oversight workflow validation | NOT MET |
| G-07 | Clinically appropriate threshold selection and validation | NOT MET |
| G-08 | Monitoring and incident-response processes established | NOT MET |
| G-09 | Regulatory and compliance review | NOT MET |
| G-10 | Formal multidisciplinary deployment approval | NOT MET |

### Current Go/No-Go Decision

**Decision: NO-GO**

**Deployment Status: NOT READY FOR CLINICAL DEPLOYMENT**

The current AI Readmission Prevention Model is a portfolio prototype developed using synthetic data. Its results demonstrate a machine-learning workflow and provide a foundation for discussing model evaluation, risk management, and AI governance.

They do not establish clinical safety, effectiveness, fairness, generalizability, regulatory compliance, or suitability for use with real patients.

The system therefore does not satisfy the required deployment gates.

### Conditions for Reconsideration

A future deployment decision should only be reconsidered after appropriate evidence has been produced and reviewed, including:

- Validation using representative real-world data obtained and governed appropriately.
- Independent clinical evaluation.
- Subgroup and fairness analysis.
- Privacy, security, legal, regulatory, and compliance review.
- Validation of human-oversight procedures.
- Clinically justified operating thresholds.
- Documented monitoring and incident-management procedures.
- Defined rollback or suspension criteria.
- Formal approval from authorized multidisciplinary stakeholders.

Failure to satisfy a critical deployment gate should prevent deployment regardless of aggregate model performance.

### Governance Decision Principle

The purpose of AI governance is not to ensure that every AI system reaches deployment.

The purpose is to ensure that AI systems are deployed only when their intended benefits, supporting evidence, safeguards, accountability structures, and residual risks justify doing so.

In some circumstances, the correct governance decision is not to deploy.

---

## 6. NIST AI RMF Governance Mapping

This assessment uses the NIST AI Risk Management Framework (AI RMF) as a practical structure for evaluating the prototype.

| AI RMF Function | Application in This Assessment |
|---|---|
| GOVERN | Defines stakeholder responsibilities, accountability, human oversight, approval authority, and governance requirements. |
| MAP | Defines the intended purpose, affected stakeholders, operational context, potential harms, and boundaries of appropriate use. |
| MEASURE | Identifies performance, fairness, threshold, drift, and other indicators that would require evaluation and ongoing monitoring. |
| MANAGE | Establishes risk controls, deployment gates, escalation actions, change-management requirements, and the current NO-GO decision. |

Governance is treated as a continuous lifecycle responsibility rather than a one-time approval activity.

---

## 7. Governance Decision Record

**System:** AI Readmission Prevention Model  
**Assessment Type:** Portfolio Governance Risk Assessment  
**Current Decision:** NO-GO  
**Deployment Status:** NOT READY FOR CLINICAL DEPLOYMENT  

### Decision Rationale

The prototype demonstrates a functioning machine-learning approach for exploring hospital readmission risk using synthetic data.

However, the evidence currently available is insufficient to establish that the system would be safe, effective, fair, compliant, or clinically appropriate for real-world patient care.

Critical deployment gates remain unmet, including real-world validation, independent clinical evaluation, subgroup fairness analysis, privacy and security review, regulatory assessment, validated human-oversight procedures, and formal multidisciplinary approval.

The appropriate governance decision at this stage is therefore to prevent clinical deployment while allowing continued research, testing, documentation, and controlled portfolio experimentation.

### Decision Owner

For this portfolio demonstration, the governance decision is documented by the project owner.

In a real healthcare organization, deployment authority should reside with appropriately authorized multidisciplinary stakeholders rather than the individual model developer.

### Reassessment Trigger

The NO-GO decision may be reconsidered if substantial new evidence becomes available or if the system, intended use, target population, data, model, threshold, or operational environment materially changes.

Any reassessment should be documented as a new governance decision rather than silently replacing this record.

---

## 8. Conclusion

The AI Readmission Prevention Model demonstrates that responsible AI development requires more than building a model with acceptable experimental performance.

A complete AI lifecycle includes defining intended use, identifying affected stakeholders, evaluating potential harms, assigning accountability, establishing human oversight, measuring performance and fairness, monitoring for change, implementing controls, and maintaining explicit deployment decision authority.

For the current synthetic prototype, the responsible governance outcome is clear:

> **NO-GO — NOT READY FOR CLINICAL DEPLOYMENT**

The model remains appropriate for education, portfolio demonstration, continued experimentation, and responsible AI governance analysis.

---

## References

- National Institute of Standards and Technology (NIST), *Artificial Intelligence Risk Management Framework (AI RMF 1.0)*.
- NIST AI Resource Center, *AI RMF Playbook*.
- U.S. Food and Drug Administration (FDA), *Clinical Decision Support Software: Guidance for Industry and Food and Drug Administration Staff*.

---

*Mission AI 2027 — Responsible, interpretable, ROI-driven AI.*

